Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer

Abstract

<i>Keap1</i> deletion confers chemoresistance in murine lung cancer cells. Patients with metastatic NSCLC with mutations in <i>KEAP1, NFE2L2</i>, or <i>CUL3</i> have shorter TTF and OS after first-line platinum doublet chemotherapy compared with matched controls. Novel approaches for improving outcomes in this subset of patients with NSCLC are therefore needed.